Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

5.17
+0.18003.61%
Post-market: 5.15-0.0200-0.39%19:25 EDT
Volume:1.98M
Turnover:10.23M
Market Cap:378.67M
PE:-7.17
High:5.24
Open:5.01
Low:4.99
Close:4.99
52wk High:9.08
52wk Low:4.25
Shares:73.24M
Float Shares:45.48M
Volume Ratio:1.45
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.7210
ROE:-64.58%
ROA:-25.95%
PB:7.29
PE(LYR):-7.17

Loading ...

Candel Therapeutics Grants New Employee Stock Options Under 2025 Inducement Plan

Reuters
·
Feb 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 03

Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)

Simply Wall St.
·
Jan 17

Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy

Reuters
·
Jan 12

Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation

Reuters
·
Dec 11, 2025

Candel Therapeutics Price Target Maintained With a $15.00/Share by Stephens & Co.

Dow Jones
·
Dec 08, 2025

Candel Therapeutics Q3 Net Income USD -11.269 Million

Reuters
·
Nov 20, 2025

Candel Therapeutics Hosts Virtual R&D Event Showcasing Immunotherapy Pipeline

Reuters
·
Nov 18, 2025

Candel Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 15, 2025

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TIPRANKS
·
Nov 14, 2025

Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)

TIPRANKS
·
Nov 14, 2025

Candel Therapeutics Advances Cancer Therapies with Strong Q3

TIPRANKS
·
Nov 14, 2025

Candel Therapeutics Showcases Progress of CAN-2409 and Pipeline Advancements in Cancer Immunotherapy

Reuters
·
Nov 13, 2025

Candel Therapeutics Q3 net loss widens to $11.3 mln

Reuters
·
Nov 13, 2025

BRIEF-Candel Therapeutics Q3 Net Income USD -11.269 Million

Reuters
·
Nov 13, 2025

Candel Therapeutics Q3 Basic EPS USD -0.21

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics Q3 Income From Operations USD -13.207 Million VS. Ibes Estimate USD -11.8 Million

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics Inc: Expect Phase 2 Nsclc Long-Term Survivor Data in Q1 2026 and Phase 3 Initiation in Q2 2026

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics Inc Qtrly Net Loss per Share $0.21

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics announces it will deliver three presentations at SITC

TIPRANKS
·
Nov 04, 2025